Equities

IND Swift Laboratories Ltd

INDSWFTLAB:NSI

IND Swift Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)136.85
  • Today's Change2.30 / 1.71%
  • Shares traded28.36k
  • 1 Year change+55.07%
  • Beta0.0762
Data delayed at least 15 minutes, as of Sep 20 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments362350604
Total Receivables, Net2,1376,7055,648
Total Inventory1054,3864,285
Prepaid expenses619096
Other current assets, total3,947114120
Total current assets6,61111,64510,753
Property, plant & equipment, net545,9276,368
Goodwill, net------
Intangibles, net--010.00
Long term investments1,133360347
Note receivable - long term3,534----
Other long term assets0.009.5610
Total assets11,65118,24118,008
LIABILITIES
Accounts payable9402,0401,760
Accrued expenses------
Notes payable/short-term debt5500
Current portion long-term debt/capital leases01,0901,047
Other current liabilities, total1,218581538
Total current liabilities2,2133,7113,345
Total long term debt1127,5318,483
Total debt1668,6219,530
Deferred income tax------
Minority interest(0.17)0(1.1)
Other liabilities, total12179172
Total liabilities2,33611,42111,998
SHAREHOLDERS EQUITY
Common stock591598598
Additional paid-in capital3,0733,0733,073
Retained earnings (accumulated deficit)5,6781,338401
Treasury stock - common------
Unrealized gain (loss)01,8341,965
Other equity, total(28)(24)(27)
Total equity9,3156,8196,010
Total liabilities & shareholders' equity11,65118,24118,008
Total common shares outstanding595959
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.